IAG933 in RAS-MAPK-Altered Cancers

1. Introduction

The evolutionarily conserved Hippo signaling pathway plays a fundamental role in regulating cell proliferation, apoptosis, and organ size control ^[2]. The core of this pathway involves a kinase cascade that ultimately regulates the downstream effector proteins, Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) ^[1]. Because YAP and TAZ lack intrinsic DNA-binding domains, they must translocate to the nucleus and interact with transcription factors, predominantly the TEAD (TEA/ATTS domain) family (TEAD1-4), to drive the transcription of oncogenic and pro-proliferative genes ^[2].

Dysregulation of the Hippo pathway and the subsequent hyperactivation of the YAP/TAZ-TEAD transcriptional complex are heavily implicated in tumorigenesis, metastasis, metabolic reprogramming, and acquired resistance to therapies across multiple human malignancies, including colorectal cancer (CRC) and RAS-MAPK-altered cancers ^[1]. Consequently, disrupting the YAP/TAZ-TEAD interaction has emerged as a highly attractive therapeutic strategy. While early efforts focused on allosteric inhibitors targeting the central lipid pocket of TEAD, recent breakthroughs have led to the development of direct surface disruptors. IAG933, developed by Novartis, represents a major milestone in this field as a potent, direct small-molecule protein-protein interaction disruptor (PPID) that has successfully entered clinical testing for the treatment of Hippo-dependent and RAS-MAPK-altered cancers ^[1][2].

2. Pharmacological Activity

IAG933 is a selective disruptor of the YAP-TEAD protein-protein binding interaction ^[1]. By directly competing at the surface interface where YAP/TAZ binds to TEAD, IAG933 effectively suppresses YAP/TAZ transcriptional output, thereby inhibiting tumor growth and proliferation driven by this axis ^[1][2].

Pharmacologically, IAG933 has shown robust preclinical biological activity both in vitro and in vivo, demonstrating the feasibility of targeting the YAP/TAZ-TEAD complex with non-peptide small molecules ^[2]. Its potent activity has led to its evaluation in a Phase I clinical trial (NCT04857372). This trial investigates IAG933 in patients with advanced solid tumors, specifically targeting malignant mesothelioma and other tumors harboring NF2/LATS1/2 mutations or YAP/TAZ fusions ^[1]. Furthermore, recent literature highlights the pharmacological efficacy of IAG933 in directly and selectively inhibiting not only Hippo-dependent tumors but also RAS-MAPK-altered cancers, expanding its potential therapeutic utility in oncology ^[1].

3. Molecular Mechanism of Action

The molecular mechanism of IAG933 centers on the direct disruption of the YAP/TAZ-TEAD protein-protein interaction. The TEAD protein features distinct surface binding sites for its coregulators, primarily categorized into interface 1 (beta strand), interface 2 (alpha helix), and interface 3 (twisted-coil region or omega-loop) ^[2]. IAG933 specifically targets interface 3 ^[2].

Interface 3 contains a deep and broad surface pocket on TEAD that normally interacts with key hydrophobic side chains of YAP (such as Met86, Leu91, and Phe95) or TAZ (such as Trp43) ^[2]. IAG933 binds deeply into this hydrophobic cavity at interface 3, acting as a direct surface disruptor. By occupying this critical hotspot, IAG933 prevents YAP and TAZ from docking onto TEAD. This blockade prevents the formation of the functional YAP/TAZ-TEAD transcriptional complex, thereby silencing the downstream expression of oncogenic target genes that are essential for tumor survival, proliferation, and metastasis ^[1][2].

4. Structure-Activity Relationship (SAR)

The discovery and optimization of IAG933 represent a significant breakthrough in structure-based rational drug design, particularly in transitioning from peptidomimetics to small molecules. The groundwork for IAG933 was laid by the design of linear YAP peptidomimetics ^[2]. Researchers utilized virtual screening to identify small-molecule mimics of chlorotryptophane, a residue in the linear YAP peptide that mimics the TAZ Trp43 (W43) residue—a known hotspot for TAZ-TEAD interaction at interface 3 ^[2].

This screening identified a dihydrobenzofuran core as an initial hit that could bind deeply into the interface 3 hydrophobic cavity. Through rigorous medicinal chemistry and structure-based rational drug design, researchers introduced a 4-phenyl substituent to the benzofuran core (yielding "compound 3"), which boosted the binding affinity by two orders of magnitude ^[2]. Further optimization led to highly potent derivatives (such as "compound 6") that improved the binding affinity of the initial hit by five orders of magnitude, achieving single-digit nanomolar IC50 values and demonstrating strong inhibition of YAP-TEAD complex formation as measured by TR-FRET ^[2]. By strategically targeting centralized hotspots, the developers of IAG933 effectively reduced the need for the small molecule to occupy the entire large, flat protein-protein interface, achieving high potency through precise structural mimicry ^[2].

5. Current Limitations

Despite the breakthrough represented by IAG933, the development of direct small-molecule PPIDs targeting the TEAD surface remains inherently challenging. The primary limitation lies in the biophysical nature of the YAP/TAZ-TEAD interaction interfaces. The interaction surfaces are exceptionally large (spanning approximately 1900 Å2) and are generally broad and shallow ^[2].

Because traditional small molecules struggle to cover such expansive and flat areas, strategically designing non-peptide small molecules that can achieve sufficient binding affinity and disrupt the interaction at interface 2 or interface 3 is significantly more difficult compared to developing allosteric inhibitors that bind to the deep, hydrophobic central lipid pocket of TEAD ^[2]. While IAG933 successfully targets interface 3, developing inhibitors for interface 2 is noted to be particularly challenging due to the dynamic and complex nature of its binding hotspots ^[2]. Consequently, direct surface disruptors are still rare, and the field relies heavily on overcoming these structural hurdles to generate diverse chemical scaffolds.

6. Future Perspectives

The successful development and clinical entry of IAG933 provide strong motivation for the continued exploration of direct surface TEAD inhibitors ^[2]. The outcomes of the ongoing Phase I clinical trials for IAG933 will be critical in validating TEAD as a safe and efficient therapeutic target in human oncology ^[1][2].

Moving forward, the insights gained from the structure-activity relationship of IAG933—specifically the strategy of leveraging centralized interaction hotspots to bypass the need for large surface area occupancy—will guide the design of next-generation PPIDs ^[2]. Furthermore, as evidence emerges regarding the efficacy of IAG933 in RAS-MAPK-altered cancers ^[1], future research will likely expand the clinical indications for TEAD inhibitors beyond strictly Hippo-mutated tumors. Validated PPIDs like IAG933 will also serve as invaluable chemical probes to further explore the complex biology of the Hippo pathway in cancer resistance, metabolic reprogramming, and tumor microenvironment regulation, ultimately paving the way for novel combination therapies in precision medicine ^[1][2].

7. References